One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study.
Hubert SchrezenmeierAustin KulasekararajLindsay MitchellFlore Sicre de FontbruneTimothy DevosShinichiro OkamotoRichard WellsScott T RottinghausPeng LiuStephan OrtizJong Wook LeeGérard SociéPublished in: Therapeutic advances in hematology (2020)
ClinicalTrials.gov identifier, NCT02946463.